	US 12,188,950 B2
	Blood biomarkers and diagnostic methods for small vessel diseases
Joseph F. Arboleda-Velasquez, Newton, MA (US)
Assigned to The Schepens Eye Research Institute, Inc., Boston, MA (US)
Filed by The Schepens Eye Research Institute, Inc., Boston, MA (US)
Filed on Nov. 22, 2022, as Appl. No. 17/992,529.
Application 17/992,529 is a continuation of application No. 16/499,192, abandoned, previously published as PCT/US2018/024394, filed on Mar. 26, 2018.
Claims priority of provisional application 62/477,274, filed on Mar. 27, 2017.
Prior Publication US 2023/0078745 A1, Mar. 16, 2023
Int. Cl. C07K 16/28 (2006.01); G01N 33/50 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01); C07K 14/71 (2006.01); C07K 14/78 (2006.01); C12N 9/64 (2006.01)

CPC G01N 33/6896 (2013.01) [C07K 16/28 (2013.01); G01N 2333/65 (2013.01); G01N 2333/705 (2013.01); G01N 2333/78 (2013.01); G01N 2333/96433 (2013.01); G01N 2800/042 (2013.01); G01N 2800/164 (2013.01); G01N 2800/2871 (2013.01); G01N 2800/56 (2013.01)]

20 Claims

1. A method comprising:

providing a test sample from a subject comprising whole blood, plasma, or serum;

assaying the sample to determine a level of: (i) Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) extracellular domain (N3ECD), (ii) collagen18α1/endostatin and (iii), High-Temperature Requirement A Serine Peptidase 1 (HTRA1) in the test sample.